Primary care physicians and laypersons’ perceptions of multicancer detection clinical trial designs
This study yielded important insights to guide trial design in planning prospective evaluation of multicancer detection testing. Maintaining transparency and trust while possibly withholding multicancer detection test results to maximize trial feasibility and efficiency is of particular concern.
Authors
- Goli Samimi (ORCID: https://orcid.org/0000-0002-0674-003X)
- Lori M. Minasian
- Elyse LeeVan (ORCID: https://orcid.org/0000-0002-2581-9747)
- Sarah M. Temkin (ORCID: https://orcid.org/0000-0002-6472-2745)
- Carol J. Weil (ORCID: https://orcid.org/0000-0003-2526-5569)
- Wendy S. Rubinstein (ORCID: https://orcid.org/0000-0002-8790-9959)
- Paul K. J. Han (ORCID: https://orcid.org/0000-0003-0165-1940)
- Tessa Swigart
- Sarah Caban
- Katherine Dent
Institutions
- National Institutes of Health (US)
- National Human Genome Research Institute (US)
- Office of the Director (US)
- National Cancer Institute (US)
- ICF International (United States) (US)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1093/jncics/pkae084
- Citations
- 2
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 1.09
Funders
- National Cancer Institute